Viridian Therapeutics Inc (VRDN) is -93.97% away from 50-day simple Moving Average despite all headwinds

Viridian Therapeutics Inc (NASDAQ: VRDN) kicked off on Friday, up 18.52% from the previous trading day, before settling in for the closing price of $39.27. Over the past 52 weeks, VRDN has traded in a range of $10.93-$35.35.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Annual sales at Healthcare sector company grew by 4.68% over the past five years. While this was happening, its average annual earnings per share was recorded -21.91%. With a float of $48.22 million, this company’s outstanding shares have now reached $52.59 million.

Viridian Therapeutics Inc (VRDN) Insider and Institutional Ownership

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 8.30%, while institutional ownership is 91.14%. The most recent insider transaction that took place on Jan 22, was worth 9,999,990. In this transaction Director of this company bought 476,190 shares at a rate of $21.00, taking the stock ownership to the 1,839,954 shares. Before that another transaction happened on Jun 16, when Company’s Chief Legal Officer sold 27 for $28.35, making the entire transaction worth $765. This insider now owns 29,971 shares in total.

Viridian Therapeutics Inc (VRDN) Latest Financial update

In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$1.09 earnings per share (EPS), higher than consensus estimate (set at -$1.27) by $0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -21.91% per share during the next fiscal year.

Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators

Take a look at Viridian Therapeutics Inc’s (VRDN) current performance indicators. Last quarter, stock had a quick ratio of 13.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2782.76.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.11, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -4.18 in one year’s time.

Technical Analysis of Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (NASDAQ: VRDN) saw its 5-day average volume 0.77 million, a negative change from its year-to-date volume of 0.94 million. As of the previous 9 days, the stock’s Stochastic %D was 27.77%. Additionally, its Average True Range was 1.15.

During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 57.30%, which indicates a significant increase from 43.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.33% in the past 14 days, which was lower than the 65.33% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $20.05, while its 200-day Moving Average is $19.66. Nevertheless, the first resistance level for the watch stands at $19.04 in the near term. At $19.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.15. If the price goes on to break the first support level at $17.92, it is likely to go to the next support level at $17.32. The third support level lies at $16.81 if the price breaches the second support level.

Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats

The company with the Market Capitalisation of 973.97 million has total of 52,586K Shares Outstanding. Its annual sales at the moment are 1,770 K in contrast with the sum of -129,870 K annual income. Company’s last quarter sales were recorded 70 K and last quarter income was -47,660 K.